Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNIOR STRENGTH MOTRIN vs OFIRMEV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.
FDA-approved for relief of mild to moderate pain,fever reduction,off-label uses include migraine and dysmenorrhea
Management of mild to moderate pain,Management of moderate to severe pain with adjunctive opioid analgesics,Reduction of fever
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
Terminal elimination half-life is 2-3 hours in adults (2.5-3 hours in children). Clinically, dosing every 4-6 hours is needed to maintain therapeutic levels.
Primarily hepatic via CYP2C9, with minor contributions from CYP2C8 and glucuronidation.
Acetaminophen is primarily metabolized in the liver via conjugation with glucuronide (50-60%) and sulfate (20-30%). A minor amount is oxidized by cytochrome P450 (CYP2E1, CYP1A2, CYP3A4) to a toxic reactive metabolite (NAPQI), which is normally detoxified by glutathione. At toxic doses, glutathione is depleted, leading to NAPQI accumulation and hepatotoxicity.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
Primarily renal (85% as sulfate and glucuronide conjugates, 10% as unchanged drug). Less than 5% fecal/biliary.
99% bound to albumin.
10-25% bound to albumin at therapeutic concentrations.
0.2 L/kg in children; low Vd indicates limited tissue distribution and high plasma protein binding. Clinical: mainly confined to vascular compartment.
0.8-1.0 L/kg. Indicates distribution into total body water.
Oral: 80-100% (rapid absorption); rectal: approximately 70-80%.
100% (intravenous); not applicable for other routes as OFIRMEV is IV only.
GFR 30-59 m L/min: reduce dose by 50% or avoid; GFR <30 m L/min: contraindicated.
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, extend dosing interval to every 8 hours; maximum daily dose 3000 mg.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce total daily dose by 50% (max 2000 mg/day). Child-Pugh Class C: Contraindicated or use with extreme caution; reduce dose to 50% of standard and extend interval to every 8 hours; maximum 2000 mg/day.
6 months to 12 years: 5-10 mg/kg per dose orally every 6-8 hours; maximum 40 mg/kg/day.
Weight-based: <10 kg: 7.5 mg/kg/dose every 6 hours; 10-50 kg: 15 mg/kg/dose every 6 hours; >50 kg: 1000 mg every 6 hours or 650 mg every 4 hours. Maximum single dose: 15 mg/kg (up to 1000 mg); maximum daily dose: 75 mg/kg (up to 4000 mg).
Initiate at lowest effective dose; consider renal function; increase dosing interval to every 6-8 hours.
No specific dose adjustment; consider reduced renal function. For Cr Cl <30 m L/min, extend interval to every 8 hours. Maximum daily dose: 3000 mg in frail elderly or with comorbidities.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
Risk of GI ulceration, bleeding, and perforation; increased cardiovascular thrombotic events; hypertension; fluid retention and edema; severe skin reactions (e.g., Stevens-Johnson syndrome); renal toxicity, especially in patients with impaired renal function; anaphylactoid reactions.
Risk of serious hepatotoxicity, especially with doses >4000 mg/day or in patients with underlying liver disease,Risk of severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis) – discontinue at first sign of rash,Risk of hypersensitivity reactions including anaphylaxis,Use caution in patients with severe hepatic impairment, active hepatic disease, or alcoholism,Avoid concurrent use of other acetaminophen-containing products
Hypersensitivity to ibuprofen or any NSAID; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; severe renal impairment; history of GI bleeding or perforation related to NSAIDs.
Known hypersensitivity to acetaminophen or any component of the formulation,Severe hepatic impairment or active liver disease (relative contraindication without black box)
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol while taking this medication as it increases risk of stomach bleeding.
No known food interactions. However, avoid excessive alcohol consumption as it may increase the risk of liver damage.
First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second trimester: Generally considered lower risk, but avoid prolonged use. Third trimester: Known association with premature closure of the ductus arteriosus, oligohydramnios, and fetal renal dysfunction; contraindicated after 30 weeks gestation.
Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dose use in third trimester may be associated with preterm birth or low birth weight. Avoid prolonged use above recommended doses.
Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01-0.02). Peak milk concentration occurs 1-2 hours after maternal dose. Due to the low concentration and short half-life in infants, ibuprofen is considered compatible with breastfeeding when used at recommended doses for short durations.
Acetaminophen is excreted in breast milk in low concentrations (M/P ratio approximately 0.9-1.0). Considered compatible with breastfeeding; peak milk levels occur 1-2 hours after maternal dosing. Use lowest effective dose for shortest duration.
No specific dose adjustment is recommended in pregnancy for occasional use. However, due to pharmacokinetic changes (increased volume of distribution and clearance), lower doses may be less effective; use the lowest effective dose for the shortest duration. Avoid routine use after 20 weeks due to fetal risks.
No dose adjustment required during pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, clearance) may lead to lower peak concentrations but standard dosing remains effective. Maximum single dose: 1 g; maximum daily dose: 4 g.
For pediatric patients, use weight-based dosing (5-10 mg/kg/dose) rather than age-based to ensure efficacy and safety. Limit to 4 doses per day; maximum 40 mg/kg/day or 1.2 g/day, whichever is less. Do not combine with other NSAIDs. Use lowest effective dose for shortest duration. Contraindicated in children with active peptic ulcer disease, severe renal impairment, or known hypersensitivity to ibuprofen or aspirin.
OFIRMEV (acetaminophen) injection is an IV formulation of acetaminophen used for pain and fever management. It is a prodrug that requires no hepatic conversion, providing rapid onset of action. Monitor for hepatotoxicity; maximum daily dose is 4 grams in adults but lower in patients with hepatic impairment or malnutrition. Do not exceed 1 gram per dose. Hypotension and anaphylaxis have been reported. Not interchangeable with oral acetaminophen due to dose equivalency. Use with caution in patients with alcohol use disorder.
Give with food or milk to reduce stomach upset.,Use weight-based dosing: shake suspension well before use; use dosing syringe or cup provided.,Do not exceed 4 doses in 24 hours; wait at least 4 hours between doses.,Do not give with other pain relievers containing ibuprofen, naproxen, or aspirin.,Stop use and consult doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Seek medical help immediately if signs of allergic reaction (rash, hives, swelling, trouble breathing) or stomach bleeding (bloody or black stools, vomit that looks like coffee grounds) occur.
OFIRMEV is given intravenously for pain or fever.,Do not take additional acetaminophen-containing medications while receiving OFIRMEV.,Report any signs of allergic reaction (rash, itching, swelling, trouble breathing).,Seek immediate medical attention if you experience severe abdominal pain, yellowing of skin or eyes, or dark urine.,Inform your healthcare provider about all medications you are taking, especially blood thinners.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNIOR STRENGTH MOTRIN vs OFIRMEV, answered by our medical review team.
JUNIOR STRENGTH MOTRIN is a NSAID Analgesic that works by Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. OFIRMEV is a Non-opioid Analgesic that works by OFIRMEV (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism of action is not fully understood, but it is thought to involve inhibition of cyclooxygenase (COX) enzymes in the central nervous system, with minimal peripheral COX inhibition. It may also act on serotonergic pathways and cannabinoid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNIOR STRENGTH MOTRIN and OFIRMEV depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNIOR STRENGTH MOTRIN is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.. The standard adult dose of OFIRMEV is: IV: 1000 mg every 6 hours or 650 mg every 4 hours; maximum single dose: 1000 mg; minimum dosing interval: 4 hours; maximum daily dose: 4000 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNIOR STRENGTH MOTRIN and OFIRMEV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNIOR STRENGTH MOTRIN is classified as Category C. First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second t. OFIRMEV is classified as Category C. Acetaminophen (OFIRMEV) is generally considered low risk across all trimesters. No increased risk of major congenital anomalies has been consistently demonstrated. Chronic high-dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.